Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Auto-DC and Allo-DC Secretome in Advanced Nasopharyngeal Cancer
NCT05261750Phase 2Active, not recruiting
- Sponsor
- Prodia Stem Cell Indonesia
- Start
- Apr 2022
- Primary completion
- Feb 2026
- Modality
- Whole Cell Cancer Vaccines, Lipid-based Nanoparticles, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of autologous dendritic cell therapy (PT. Prodia Stem Cell Indonesia) and allogeneic dendritic cell secretome in nasopharyngeal carcinoma (NPC) (3 arms), sponsored by Prodia Stem Cell Indonesia. Primary endpoint: Karnofsky Performance Status at 3 months. Started Apr 2022; status: active, not recruiting.
02
Drugs
autologous dendritic cell therapy (PT. Prodia Stem Cell Indonesia)allogeneic dendritic cell secretome
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05261750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05261750.